Explore the words cloud of the MEDIVAC project. It provides you a very rough idea of what is the project "MEDIVAC" about.
The following table provides information about the project.
|Coordinator Country||Norway [NO]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
|Duration (year-month-day)||from 2017-06-01 to 2017-10-31|
Take a look of project's partnership.
Cancer remains a leading cause of disease and death worldwide. An estimated 14m new cancer cases were diagnosed in 2012 and 22m are predicted by 2023. Immunotherapy and particularly personalized neoantigen-based vaccines represent an exciting new weapon in the war against cancer, as they are specific to the tumor and potentially safer and more effective than other types of treatment. However, the design of neoantigen-based cancer vaccines is currently hampered by an inability to reliably select immunogenic neoantigens using the existing technologies. OncoImmunity proposes to develop disruptive software - MEDIVAC - for the rapid and intelligent design of neoantigen-based personalized cancer vaccines, tailored to specific vaccine deliver systems (VDS). The software will leverage a machine-learning framework being developed at OncoImmunity that addresses key prediction gaps in the field of neoantigen discovery. Preliminary testing of MEDIVAC´s prediction engine reveals that it can identify immunogenic neoantigens with an unprecedented level of accuracy, and at a fraction of the time and cost of competing wet-lab methodologies. The MEDIVAC technology will enable personalized cancer vaccine companies to make safer more efficacious vaccines in an affordable and clinically actionable timeframe, and will consequently help revolutionize the treatment of cancer. We believe the SME instrument is the ideal funding vehicle to enable OncoImmunity to overcome the remaining barriers to the market and establish the company as the leading provider of software solutions for guiding the design of cancer vaccines. Furthermore, the MEDIVAC software will help nurture and improve the competitiveness of European companies in the rapidly growing personalized cancer vaccine market, and ultimately help Europe to tackle a global cancer epidemic.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEDIVAC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MEDIVAC" are provided by the European Opendata Portal: CORDIS opendata.
CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical researchRead More
Delivering BEACON Caresystem – a ground-breaking ICT-enabled ICU bed-side assistant providing recommenda-tions for critical mechanical ventilation support for better care and reduced costs.Read More
SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.Read More